(Q36302943)

13 August 2017

1 reference

title

Treatment of psoriatic arthropathy (English)

1 reference

Anesthesiology and pain medicine

13 August 2017

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

17 October 2022

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

17 October 2022

author name string

P. Goupille

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1626281

17 October 2022

D. Soutif

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1626281

17 October 2022

J. P. Valat

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1626281

17 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1626281

17 October 2022

publication date

1 June 1992

1 reference

full work available at URL

13 August 2017

https://api.elsevier.com/content/article/PII:004901729290036D?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

https://api.elsevier.com/content/article/PII:004901729290036D?httpAccept=text/plain

17 October 2022

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Seminars in Arthritis and Rheumatism

17 October 2022

published in

1 reference

13 August 2017

21

1 reference

13 August 2017

6

1 reference

13 August 2017

355-367

1 reference

Psoriatic arthritis: A clinical, immunologic and HLA study of 100 patients

13 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Familial occurrence of psoriatic arthritis

17 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease

17 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Gold salts in the treatment of rheumatoid arthritis. A double-blind study

17 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Chrysotherapy in rheumatoid arthritis

17 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis

17 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Rheumatism and psoriasis: a re-evaluation

17 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Gold in psoriatic arthopathy

17 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis

17 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Long term experience with oral gold in psoriatic arthritis

17 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Clinical response to auranofin in patients with psoriatic arthritis

17 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Psoriatic arthritis. Long term treatment with auranofin

17 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

D-penicillamine and psoriatic arthropathy

17 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

17 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Action of synthetic antimalarial drugs on psoriasis

17 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Psoriatic arthritis. Follow-up study

17 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

17 October 2022

Atabrine in psoriasis

53

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

THE APPLICATION OF FLUORESCENCE ASSAY TO THE IDENTIFICATION OF ACIDIC COMPONENTS IN PSORIATIC LESIONS

17 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

17 October 2022

Psoriasis and arthritis

60

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

PSORIASIS, ULTRAVIOLET LIGHT, AND CHLOROQUINE.

17 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Psoriatic arthritis. A complete clinical study of 86 patients

17 October 2022

62

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Antimalarials in psoriatic arthritis

17 October 2022

63

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of pustular psoriasis and pustular bacterid with quinacrine (atabrine)

17 October 2022

65

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Amethopterin (methotrexate) in connective tissue disease-psoriasis and polyarthritis

17 October 2022

76

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Methotrexate in psoriatic arthritis: a retrospective study

17 October 2022

77

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Methotrexate treatment of psoriatic arthritis

17 October 2022

78

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Weekly intravenous methotrexate in the treatment of rheumatoid arthritis

17 October 2022

79

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Efficacy of low-dose methotrexate in rheumatoid arthritis

17 October 2022

80

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

17 October 2022

82

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Methotrexate and retinoids in combination for psoriasis

17 October 2022

83

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Short-term, High-dose Methotrexate Therapy in a Case of Severe Psoriatic Arthritis

17 October 2022

84

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriatic arthropathy with either azathioprine or methotrexate.

17 October 2022

87

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriasis with mercaptopurine

17 October 2022

89

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriatic arthritis with 6-mercaptopurine

17 October 2022

90

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Beneficial Effects of Triacetyl Azauridine in Psoriasis and Mycosis Fungoides

17 October 2022

91

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

A double-blind study of azaribine in the treatment of psoriasis

17 October 2022

92

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriatic arthritis with azaribine

17 October 2022

93

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Short-term use of cyclosporin A in severe psoriasis

17 October 2022

94

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Cyclosporin for psoriasis

17 October 2022

98

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Cyclosporine improves psoriasis in a double-blind study

17 October 2022

99

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of resistant severe psoriasis with systemic cyclosporine.

17 October 2022

100

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A

17 October 2022

101

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Low-dose cyclosporin A in severe psoriasis. A double-blind study

17 October 2022

102

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Multisystem crystalline deposits. Primary hyperoxaluria

17 October 2022

103

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Cyclosporin A in psoriatic arthritis: an open study

17 October 2022

104

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis

17 October 2022

107

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Photochemotherapy and psoriatic arthritis. A prospective study

17 October 2022

109

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Vitamin A and retinoids: from nutrition to pharmacotherapy in dermatology and oncology

17 October 2022

110

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cis-retinoic acid

17 October 2022

111

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis

17 October 2022

116

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

The use of etretinate in psoriatic arthropathy

17 October 2022

117

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Comparison of etretinate (Tigason) and parenteral gold in the treatment of psoriatic arthropathy

17 October 2022

118

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Pilot study of etretinate in psoriatic arthritis

17 October 2022

120

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriatic arthropathy with etretinate: a two-year follow-up

17 October 2022

121

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Etretinate therapy for psoriasis: clinical responses, remission times, epidermal DNA and polyamine responses

17 October 2022

125

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Oral Retinoids and Psoriasis

17 October 2022

126

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis

17 October 2022

129

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study

17 October 2022

131

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study

17 October 2022

132

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

1,25-dihydroxyvitamin D3 potentiates the in vitro inhibitory effects of cyclosporin A on T cells from rheumatoid arthritis patients

17 October 2022

133

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol)

17 October 2022

134

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production

17 October 2022

135

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA

17 October 2022

136

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Psoriasis and human growth hormone: Aetiology and therapy

17 October 2022

138

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriasis with Somatostatin

17 October 2022

139

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Somatostatin treatment of psoriasis

17 October 2022

140

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Epidermal growth factor, somatostatin, and psoriasis

17 October 2022

141

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Somatostatin treatment of psoriatic arthritis

17 October 2022

144

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

17 October 2022

Cimetidine and psoriasis

145

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriasis with cimetidine

17 October 2022

148

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Gamma interferon in psoriatic arthritis

17 October 2022

152

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Gamma interferon and psoriasis

17 October 2022

153

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Treatment of psoriatic arthritis with bromocriptine

17 October 2022

154

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia

17 October 2022

155

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

Peptide T in treatment of AIDS

17 October 2022

157

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90036-D

17 October 2022

Identifiers

1 reference

13 August 2017

1 reference